Research programme: G protein-coupled receptor modulators - Astellas Pharma/TaiGen Biotechnology

Drug Profile

Research programme: G protein-coupled receptor modulators - Astellas Pharma/TaiGen Biotechnology

Alternative Names: GPCR modulators - Astellas/TaiGen

Latest Information Update: 01 Jun 2010

Price : $50

At a glance

  • Originator Astellas Pharma; TaiGen Biotechnology
  • Class
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Immunological disorders; Inflammation

Most Recent Events

  • 01 Jun 2010 Development discontinued for Immunological disorders before 2010
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 28 Mar 2003 Preclinical trials in Immunological disorders in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top